Patients with gynecologic cancers who have Medicaid coverage are more likely to feel increased financial distress, anxiety about their cancer, and increased general anxiety during the pandemic if their annual income is less than $40,000, according to a new study from Weill Cornell Medicine investigators.
A study, published in Mayo Clinic Proceedings, demonstrates that Cologuard (mt-sDNA) is the most cost-effective colorectal cancer screening option in the Alaska Native population, as compared to colonoscopy and the fecal immunochemical test, for a wide range of adherence scenarios.
Concerns about fertility often influence how young women with breast cancer approach treatment decisions and are a reason for forgoing or delaying hormone-blocking therapy, a new study by Dana-Farber Cancer Institute investigators shows.
The American College of Radiology Data Science Institute and the Cancer Imaging Archive, funded by NCI, have teamed up to connect use cases and datasets to speed medical imaging artificial intelligence development.
Researchers at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute have identified molecular patterns linked to patients developing resistance to certain therapies.
Patients with advanced colorectal cancer may be spared from a toxic side effect caused by a type of targeted therapy used to treat the cancer with the help of another drug normally used to treat melanoma.
Targeting a pathway that is essential for the survival of certain types of acute myeloid leukaemia could provide a new therapy avenue for patients, researchers from Wellcome Sanger Institute found.
Zynlonta (loncastuximab tesirine-lpyl), a CD19-directed antibody and alkylating agent conjugate, was granted FDA Accelerated Approval for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma not otherwise specified, DLBCL arising from low grade lymphoma, and high-grade B-cell lymphoma.
The Ventana MMR RxDx Panel has received FDA approval for advanced or recurrent endometrial cancer patients.
Mobocertinib (TAK-788) has received FDA Priority Review for the treatment of adult patients with epidermal growth factor receptor Exon20 insertion mutation-positive (insertion+) metastatic non-small cell lung cancer, as detected by an FDA-approved test, who have received prior platinum-based chemotherapy.
